Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | BCHE | P06276 | 1/20 | 0.60 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.60 |
| ▸ | TRPC4 | Q9UBN4 | 1/20 | 0.60 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.60 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.51 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.51 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL370673 | 0.87 | PKM (0.67) | PKMBCHEDDAH1POLBSMN1; SMN2 | |
| SCHEMBL11360890 | 0.85 | PKM (0.56) | PKMDDAH1POLBRAB9ASLC40A1 | |
| SCHEMBL825211 | 0.84 | PKM (0.59) | PKMBCHEDDAH1POLBRAB9A | |
| SCHEMBL8443937 | 0.84 | PKM (0.68) | PKMBCHEDDAH1POLBSMN1; SMN2 | |
| SCHEMBL19012922 | 0.84 | PKM (0.55) | PKMDDAH1POLBRAB9ASLC40A1 | |
| SCHEMBL31734838 | 0.84 | PKM (0.71) | PKMBCHEDDAH1POLBSMN1; SMN2 | |
| SCHEMBL711507 | 0.84 | PKM (0.71) | PKMBCHEDDAH1POLBSMN1; SMN2 | |
| SCHEMBL21784319 | 0.82 | PKM (0.54) | PKMDDAH1POLBSMN1; SMN2RAB9A | |
| SCHEMBL21784357 | 0.82 | PKM (0.54) | PKMDDAH1POLBSMN1; SMN2NPC1 | |
| SCHEMBL18661211 | 0.82 | PKM (0.54) | PKMDDAH1POLBSMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017068089-A2 | NOVEL FERROPORTIN INHIBITORS | VIFOR (INTERNATIONAL) AG (CH) | 2017-04-27 | — | — | WO | disclosed |
| US-6906075-B2 | Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues | NEUROGEN CORP. (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1465888-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED BENZOIMIDAZOLE ANALOGUES | NEUROGEN CORPORATION (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20030216390-A1 | Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues | NEUROGEN CORPORATION | 2003-11-20 | — | — | US | disclosed |
| WO-2003059289-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED BENZOIMIDAZOLE ANALOGUES | NEUROGEN CORPORATION (US) | 2003-07-24 | — | — | WO | disclosed |
| EP-0946180-A4 | METHOD FOR STIMULATING BONE FORMATION | SMITHKLINE BEECHAM CORP (US) | 2003-07-23 | — | — | EP | disclosed |
| EP-0767792-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-11-20 | — | — | EP | disclosed |
| US-20020032187-A1 | Method for stimulating bone formation | SMITHKLINE BEECHAM CORPORATION | 2002-03-14 | — | — | US | disclosed |
| US-5977101-A | Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0946180-A1 | METHOD FOR STIMULATING BONE FORMATION | SMITHKLINE BEECHAM CORPORATION (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998015278-A1 | METHOD FOR STIMULATING BONE FORMATION | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-16 | — | — | WO | disclosed |
| EP-0767792-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-04-16 | — | — | EP | disclosed |
| WO-1996000730-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216390-A1 | Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues | MCHR1, MCHR2, MC1R | PKM 749/4885BCHE 1917/4885TRPC3 2384/4885 |
| US-20020032187-A1 | Method for stimulating bone formation | BMP2, BMP4, SOST | PKM 4426/4885BCHE 1606/4885TRPC3 2265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.